Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease

https://www.businesswire.com/news/home/20230515005293/en/%C2%A0Therini-Bio-Initiates-First-In-Human-Dosing-in-Phase-1-Trial-of-THN391-a-Fibrin-Targeting-Therapeutic-Candidate-for-Alzheimer%E2%80%99s-Disease